As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce ...
Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the worl...
Culture Biosciences, an expert in cloud-connected bioreactor technology, and Cytiva, a Danaher company and a leader in the life sciences industry, ...
( This news story is developing.) The U.S.–India trade relationship entered dangerous new territory as former U.S. President Donald Trump an...
SERB Pharmaceuticals (“SERB”), a global specialty pharmaceutical company focused on medicines for rare diseases and medical emergencies, and ...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, announced Novasign and Repligen have entered ...
Breyanzi has the potential to be the first and only CAR T cell therapy approved for MZL, addressing a high unmet need Application based on results fro...
- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has anno...
Pioneering solution provides scientists with actionable answers faster to accelerate scientific discovery CAS, a division of the American Chemical Soci...
-FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, today announced the U.S. launch of the FDR ...
AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partn...
Apellis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EMPAVELI® (pegcetacoplan) as the first tre...
POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovatio...
Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months...
© 2025 Biopharma Boardroom. All Rights Reserved.
